CANCER CYTOPATHOLOGY

metrics 2024

Connecting Research and Practice in Cancer Cytopathology

Introduction

Cancer Cytopathology, published by Wiley, is an esteemed journal that plays a pivotal role in the fields of Cancer Research and Oncology. With a focus on the microscopic examination and analysis of cancerous cells, this journal serves as a crucial platform for disseminating high-quality research aimed at improving diagnostic techniques and therapeutic strategies. The journal holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, emphasizing its influence and importance within the scientific community. Additionally, it is recognized in the top 76th percentile in Medicine - Oncology and the 63rd percentile in Cancer Research according to Scopus rankings. Operating from the United States, Cancer Cytopathology is dedicated to fostering cutting-edge research and exploration in cytopathology, providing essential insights into cancer progression and management. Researchers and practitioners alike will find this journal invaluable for staying on the forefront of advancements in cancer diagnostics.

Metrics 2024

SCIMAGO Journal Rank0.99
Journal Impact Factor2.60
Journal Impact Factor (5 years)3.10
H-Index68
Journal IF Without Self2.60
Eigen Factor0.00
Normal Eigen Factor0.63
Influence0.82
Immediacy Index0.70
Cited Half Life6.40
Citing Half Life5.80
JCI0.82
Total Documents1589
WOS Total Citations2930
SCIMAGO Total Citations12856
SCIMAGO SELF Citations1632
Scopus Journal Rank0.99
Cites / Document (2 Years)2.53
Cites / Document (3 Years)2.67
Cites / Document (4 Years)2.64

Metrics History

Rank 2024

Scopus

Oncology in Medicine
Rank #96/404
Percentile 76.24
Quartile Q1
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #84/230
Percentile 63.48
Quartile Q2

IF (Web Of Science)

ONCOLOGY
Rank 175/322
Percentile 45.80
Quartile Q3
PATHOLOGY
Rank 35/88
Percentile 60.80
Quartile Q2

JCI (Web Of Science)

ONCOLOGY
Rank 109/322
Percentile 66.15
Quartile Q2
PATHOLOGY
Rank 36/88
Percentile 59.09
Quartile Q2

Quartile History

Similar Journals

Diagnostics

Unlocking Innovations in Diagnostic Science
Publisher: MDPIISSN: Frequency: 12 issues/year

Diagnostics is a pioneering open-access journal published by MDPI, catering to the critical field of clinical biochemistry since its establishment in 2011. Based in Switzerland, this esteemed journal, with E-ISSN 2075-4418, has gained significant recognition within the academic community, reflected in its 2023 Scopus rankings placing it in Q2 for Clinical Biochemistry and showcasing its impact in related medical disciplines. With a commitment to disseminating high-quality research that advances the understanding of diagnostic techniques and methodologies, Diagnostics covers a broad spectrum of topics including biochemical markers, diagnostic imaging, and molecular diagnostics. The journal's open access model ensures that groundbreaking findings are readily available to researchers, professionals, and students alike, fostering an environment of knowledge sharing and collaboration. As the field of diagnostics continues to evolve, Diagnostics remains at the forefront, paving the way for innovations that enhance health outcomes globally.

Frontiers in Oncology

Innovating oncology through open access and collaboration.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

DIAGNOSTIC CYTOPATHOLOGY

Unveiling Insights in Cytopathology for Better Health
Publisher: WILEYISSN: 8755-1039Frequency: 12 issues/year

DIAGNOSTIC CYTOPATHOLOGY is a scholarly journal dedicated to advancing the field of cytopathology through the publication of high-quality research and reviews. Founded in 1985 and published by Wiley, this journal provides vital insights into the diagnosis and management of diseases through cytological techniques. With a strong presence in the academic community, it currently holds a Q3 ranking in the fields of Histology, Medicine (miscellaneous), and Pathology and Forensic Medicine, reflecting its commitment to fostering knowledge and innovation in these areas. Researchers and clinicians alike can benefit from its comprehensive articles that delve into cutting-edge methodologies and diagnostic strategies. Although not an Open Access journal, DIAGNOSTIC CYTOPATHOLOGY remains a crucial resource for professionals seeking to enhance their understanding and practice in the diagnostic realm. With an ISSN of 8755-1039 and an E-ISSN of 1097-0339, the journal continues to publish impactful studies well into 2024, ensuring that essential advancements in cytopathology reach a global audience.

Clinical Lung Cancer

Shaping the landscape of oncology through rigorous research.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

ACTA CYTOLOGICA

Illuminating Cellular Pathways for Future Discoveries
Publisher: KARGERISSN: 0001-5547Frequency: 6 issues/year

ACTA CYTOLOGICA is a premier journal dedicated to the field of cytology, offering a platform for researchers, professionals, and students interested in the intricate study of cellular biology and its applications in the medical domain. Published by KARGER in Switzerland, the journal has been a vital resource since its inception in 1960 and is recognized for its rigorous peer-reviewed articles. With a notable impact factor reflecting its significance—ranked in the Q2 category in both Medicine (miscellaneous) and Pathology and Forensic Medicine, and Q3 in Histology for 2023—ACTA CYTOLOGICA continues to contribute valuable insights into cytological research and its implications for clinical practice. The journal maintains an annual focus on cutting-edge studies and reviews that enhance understanding and methodological advancements in cytology. Although it does not provide open access, it remains an essential read for those involved in histology and pathology, promising to keep them abreast of the latest findings and technological innovations in the field.

PATHOLOGY & ONCOLOGY RESEARCH

Exploring the Nexus of Disease and Treatment
Publisher: FRONTIERS MEDIA SAISSN: 1219-4956Frequency: 1 issue/year

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

Oncology Letters

Advancing Cancer Research Through Innovative Insights
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

JOURNAL OF CLINICAL PATHOLOGY

Elevating Standards in Diagnostic Excellence
Publisher: BMJ PUBLISHING GROUPISSN: 0021-9746Frequency: 12 issues/year

JOURNAL OF CLINICAL PATHOLOGY, published by BMJ PUBLISHING GROUP, stands at the forefront of advancements in the field of clinical pathology, offering a platform for groundbreaking research and insights from 1948 to the present. With an impressive impact factor and categorized as Q1 in both Medicine (miscellaneous) and Pathology and Forensic Medicine for 2023, the journal holds a distinguished position in the academic community, ranking 22nd out of 208 journals in its category on Scopus and representing the 89th percentile. While the journal does not currently offer open access, it remains a vital resource for researchers, healthcare professionals, and students seeking to stay current with innovative methodologies, clinical techniques, and diagnostic advancements. Located in London, United Kingdom, the journal aims to bridge the gap between laboratory findings and clinical practice, emphasizing the importance of evidence-based pathology in improving patient care and treatment outcomes. Engage with the JOURNAL OF CLINICAL PATHOLOGY to enhance your understanding and contribute to the evolving landscape of clinical pathology research.

CYTOPATHOLOGY

Elevating Standards in Cytopathological Research
Publisher: WILEYISSN: 0956-5507Frequency: 6 issues/year

CYTOPATHOLOGY is a pivotal journal published by WILEY, focusing on the dynamic field of cytopathology within the broader medical and pathological sciences. Founded in 1990, this journal has become a crucial resource for researchers, professionals, and students interested in the microscopic examination of cell samples for diagnostic purposes. With an ISSN of 0956-5507 and E-ISSN of 1365-2303, CYTOPATHOLOGY is indexed in Scopus, where it currently holds a rank of #113 in Pathology and Forensic Medicine and #43 in Histology, placing it in the Q3 quartile for multiple categories in 2023. The journal publishes original research, reviews, and clinical studies that advance the understanding and application of cytopathology and its significance in health care. Although not an Open Access journal, its commitment to providing high-quality research makes it an essential platform for disseminating knowledge in the field. Researchers and practitioners looking to stay at the forefront of cytopathology developments will find CYTOPATHOLOGY to be an invaluable resource.

Journal of Cytology

Unlocking the Mysteries of Cells: A Journal for the Curious Mind.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0970-9371Frequency: 4 issues/year

Journal of Cytology, published by Wolters Kluwer Medknow Publications, stands as a pivotal resource in the fields of cytology, histology, and pathology. With an ISSN of 0970-9371 and an E-ISSN of 0974-5165, this peer-reviewed, open-access journal has been disseminating vital research since its inception in 1985, transitioning to open access in 2008 to enhance global accessibility to its scholarly articles. Operating from its base in Mumbai, India, the journal is categorized in the Q3 quartile for histology and pathology according to the 2023 rankings, affirming its ongoing contribution to the scientific community. Researchers and professionals can benefit from a wide array of cutting-edge studies and reviews that advance the understanding of cytological practices. The journal's commitment to disseminating high-impact research is reflected in its Scopus rankings, positioning it among the significant players in its field. By facilitating open access, the Journal of Cytology aims to foster knowledge exchange and inspire new investigations among scholars, clinicians, and students alike.